Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Background

 

Venous thromboembolism events represent a serious complication related to hormonal contraception. Venous thrombosis has the potential to be fatal and it accounts for an important part of cardiovascular mortality among young women. Women at high cardiovascular risk should avoid combined oral contraceptives. Among such women, alternative forms of contraception including progestin-only contraceptives are often used. However, the safety of these forms of contraception remains largely unknown.  

 

Study design

 

COntraception and REcurrent Venous Events (COREVE) study is a cohort study among outpatients from the Hotel-Dieu Hospital in Paris. This study aims to assess the safety of progestagen-only contraceptives as well as intrauterine contraceptive devices among women with personal history of venous thrombosis. The population study consists of premenopausal women aged 18 to 45 years with a first documented episode of venous thromboembolism.  Between 2000 and 2008, we included retrospectively about 3.000 consecutive outpatient cases. Baseline data includes detailed information on the first episode of venous thrombosis, presence of prothrombotic mutations, time of discontinuation of vitamin K antogonist therapy, reproductive factors and contraceptives use. Women will be asked to return a mailed questionnaire including information on recurrent venous thromboembolism, use and type of contraceptives. The end point of the study will be recurrent deep vein thrombosis or recurrent pulmonary embolism. Recurrent clinical events will have to be confirmed by imaging procedure. About 200 recurrent VTE events are expected.  

 

Funding

The COREVE study is supported by Inserm and by a grant from Pierre-Fabre Santé.  

© Esther 2019